Details for Patent: 7,645,459

Title:	Dosage forms of bisphosphonates
Abstract:	Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Inventor(s):	Dansereau; Richard John (Cilncinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Filing Date:	Apr 15, 2005
Application Number:	11/106,816
Claims:	1. An oral dosage form having pharmaceutically effective absorption comprising: (a) from about 1 mg to about 500 mg of a bisphosphonate which is selected from the group consisting of risedronate and acids, salts, and esters thereof; (b) from about 10 mg to about 500 mg of EDTA; and (c) a delayed release mechanism to deliver the bisphosphonate and the EDTA in the lower gastrointestinal tract. 2. The oral dosage form of claim 1 wherein the EDTA is disodium EDTA. 3. The oral dosage form of claim 1 wherein the delayed release mechanism is selected from the group consisting of pH triggered delivery systems, bacterial enzyme triggered delivery systems, time dependent delivery systems and combinations thereof. 4. The oral dosage form of claim 3 wherein the delayed release mechanism is a pH triggered delivery system. 5. The oral dosage form of claim 4 wherein the pH triggered delivery system comprises an enteric coating. 6. The oral dosage form of claim 1 comprising from about 10 mg to about 200 mg of risedronate sodium. 7. The oral dosage form of claim 6 comprising from about 75 mg to about 250 mg of the EDTA, wherein the EDTA is disodium EDTA. 8. An oral dosage form having pharmaceutically effective absorption comprising: (a) from about 1 mg to about 500 mg of risedronate sodium; (b) from about 75 mg to about 250 mg of disodium EDTA; and (c) an enteric coating which provides for release of the risedronate sodium and the disodium EDTA in the lower gastrointestinal tract of a mammal. 9. A method for treating a disease selected from the group consisting of osteoporosis, Paget's disease, hyperparathyroidism, hypercalcemia of malignancy, osteolytic bone metastasis, and combinations thereof, comprising administering to a human or other mammal in need thereof a safe and effective amount of the oral dosage form of claim 8. 10. The method of claim 9 wherein the disease is osteoporosis. 11. The method of claim 9 wherein the oral dosage form is administered according to a continuous schedule having a dosing interval selected from the group consisting of daily, weekly, three times per month, twice monthly, and once monthly. 12. The method of claim 11 wherein the oral dosage form is administered weekly. 13. The oral dosage form of claim 8 comprising from about 10 mg to about 50 mg of risedronate sodium. 14. The oral dosage form of claim 13 comprising about 100 mg of the disodium EDTA. 15. The oral dosage form of claim 14 comprising about 35 mg of risedronate sodium. 16. The oral dosage form of claim 15 wherein the enteric coating is a methacrylic acid copolymer. 17. The oral dosage form of claim 8 comprising from about 50 mg to about 200 mg of risedronate sodium. 18. The oral dosage form of claim 17 comprising about 100 mg of the disodium EDTA. 19. The oral dosage form of claim 18 comprising about 150 mg of risedronate sodium. 20. The oral dosage form of claim 19 wherein the enteric coating is a methacrylic acid copolymer. 21. A method for treating osteoporosis comprising administering to a human or other mammal in need thereof a safe and effective amount of the oral dosage form of claim 15. 22. The method of claim 21 wherein the oral dosage form is administered with or without food. 23. A method for treating osteoporosis comprising administering to a human or other mammal in need thereof a safe and effective amount of the oral dosage form of claim 19. 24. The method of claim 23 wherein the oral dosage form is administered with or without food.